Welcome to our dedicated page for Pharming Group N.V. SEC filings (Ticker: PHAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharming Group N.V. SEC filings document a foreign private issuer commercializing rare-disease medicines and reporting through Form 6-K current reports and Form 20-F annual disclosures. The filings cover financial results, revenue trends for RUCONEST® and Joenja® (leniolisib), regulatory developments for APDS, and clinical-program disclosures involving primary immunodeficiencies with immune dysregulation and napazimone (KL1333) in primary mitochondrial disease.
The company's regulatory record also includes annual-report filings, shareholder-meeting materials, auditor appointment matters, remuneration policy proposals, and authorizations related to share issuance and repurchases. These disclosures frame Pharming's governance, capital structure, commercial products, pipeline spending, licensing obligations, and rare-disease development risks.
Pharming Group announced the FDA has accepted its supplemental NDA seeking approval of leniolisib (Joenja) for children aged 4–11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The application received Priority Review with a PDUFA target action date of January 31, 2026. The sNDA is supported by positive data from a multinational, single-arm Phase III study in 4–11-year-olds showing, over 12 weeks, reductions in lymphadenopathy and increases in naïve B cells, indicating correction of the underlying immune defect; the submission also included safety data from 8 months of treatment. There are no approved treatments globally for children under 12 with APDS. Leniolisib is already approved in the U.S. for patients aged 12 and older (March 2023).
Pharming Group N.V. filed a Form 6-K to report that it has been promoted from the Euronext AScX (Small Cap) to the Euronext AMX (MidCap) index, effective September 22, 2025. The AMX index includes 25 companies selected by Euronext Amsterdam based on free-float market capitalization and liquidity, and this move marks Pharming’s return to the AMX.
The company describes this promotion as a reflection of its strong financial and pipeline growth momentum and expects AMX inclusion to increase its visibility and attractiveness to investors. Management reiterates its focus on executing commercial and pipeline catalysts as it aims to develop further as a global rare disease company.
Pharming Group announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. The release states Mr. Lynard has over 20 years of global finance leadership in life sciences, including recent CFO roles at Schoeller Allibert and Zentiva and senior finance roles at Gilead Sciences where he served as Senior Vice President and CFO for Global Commercial Operations, R&D and Manufacturing.
The company frames the hire as strengthening financial leadership following strong first half 2025 financial results and supporting Pharming's growth strategy and commercial and pipeline catalysts. Mr. Lynard holds an MSc in Business Economics and Auditing and an executive MBA from IMD.